{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.97","upperLimit":"1.00","value":"0.99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"description":"Survival is defined as time from study entry to death due to any cause. Patients alive at last contact where censored at last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim","id":"OG000","title":"Group 1"}],"paramType":"NUMBER","populationDescription":"Eligible (n=278). Follow-up for censored patients (n=277) is 76 months (range: 4.7 to 109 months).","reportingStatus":"POSTED","timeFrame":"At 60 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Probability of survival"}